Related Experiment Video
Updated: May 3, 2026
Assessing Biofilm Dispersal in Murine Wounds
Published on: August 7, 2021
Clinically Addressing Biofilm in Chronic Wounds
Christopher Attinger1, Randy Wolcott2
1Division of Wound Healing, Georgetown University Hospital , Washington, District of Columbia.
Background:
A chronic wound is a wound that is arrested in the inflammatory phase of wound healing and cannot progress further. Over 90% of chronic wounds contain bacteria and fungi living within a biofilm construct.
The Problem:
Each aggregation of microbes creates a distinct biofilm with differing characteristics so that a clinical approach has to be tailored to the specifics of a given biofilm. Defining the characteristics of that biofilm and then designing a therapeutic option particular to that biofilm is currently being defined.
Basic/Clinical Science Advances:
Biofilm becomes resistant to therapeutic maneuvers at 48-96 h after formation. By repeatedly attacking it on a regular schedule, one forces biofilm to reattach and reform during which time it is susceptible to antibiotics and host defenses. Identifying the multiple bacteria and fungi that make up a specific biofilm using polymerase chain reaction (PCR) allows directed therapeutic maneuvers such as application of specific topical antibiotics and biocides to increase the effectiveness of the debridement.
Clinical Care Relevance:
Most chronic wounds contain biofilm that perpetuate the inflammatory phase of wound healing. Combining debridement with using PCR to identify the bacteria and fungi within the biofilm allows for more targeted therapeutic maneuvers to eliminate a given biofilm.
Conclusion:
Therapeutic options in addition to debridement are currently being evaluated to address biofilm. Using PCR to direct adjunctive therapeutic maneuvers may increase the effectiveness of addressing biofilm in a chronic wound.
